IL37 and inflammatory bowel disease: Monoclonal antibody therapies inhibiting interleukin-23 and interleukin-12, including ustekinumab, are becoming an increasingly important class of therapies in treating IBD, so understanding mechanisms to optimize this class of treatment are needed.